Kornimate/medical-research-clean huggingface dataset:
stereotactic radiation to decrease pancreatic secretions

Conditions: Pancreatic Fistulae

Summary: patients that have undergone pre-operative radiation for pancreatic carcinoma, that upon pathologic examination of the normal portion of the pancreatic gland that was in the radiation field showed acute and chronic changes in the pancreatic cells. the hypothesis for utilizing stereotactic radiation on pancreatic fistulae is that the treatment will decrease pancreatic secretions, thus decreasing autodigestion.

stereotactic radiation for cancer has been utilized to successfully treat the head of the pancreas, which is generally a well-tolerated procedure with minimal complications. upon further investigation under the microscope, after resection during a complex whipple operation, it is noted that particularly the exocrine glandular tissue atrophied substantially. based on this information, the hypothesis for utilizing stereotactic radiation on the remaining pancreas is production of a fibrosis of the pancreas and a decrease in the production of exocrine portion of the gland. the use of stereotactic radiation will be performed on individuals that are non-surgical candidates.

Eligibility criteria:
inclusion criteria: * pancreatic fistula * non-surgical candidate exclusion criteria: * surgical candidate

Keywords: pancreas pancreatic fistula stereotactic radiation
seroma at the donor site of the tram flap, with or without quilting suture: a comparative study using ultrasound

Conditions: Seroma

Summary: patient undergoing breast reconstruction with lower abdominal flap, benefit when points are used for membership (between the aponeurosis of the abdominal flap and underlying muscles) for closing the donor area, where there is reduced incidence of complications.

this study evaluated seroma formation at the donor site of the tram patients who underwent breast reconstruction. forty-eight breast reconstructions were performed using the bipedicled tram flap. the patients were randomly allocated into three groups of 16 participants each: dn group, use of suction drains but no quilting sutures between the remaining abdominal flap and musculoaponeurotic layer of the anterior abdominal wall; qs+dn group, use of quilting sutures and suction drains; and qs group, use of quilting sutures but no suction drains. in order to determine seroma formation, ultrasound examinations were performed on postoperative days 7 and 14 in 5 regions of the abdominal wall: epigastric, umbilical, hypogastric, right iliac, and left iliac regions.

Eligibility criteria:
inclusion criteria: * were age between 20 and 65 years * body mass index (bmi) ≤ 30 kg/m2 * non-smokers. exclusion criteria: * no skin excess in the infraumbilical region * previous abdominoplasty * uncontrolled systemic disease * such as diabetes mellitus and arterial hypertension * collagen diseases * psychiatric disorders * large weight loss * and/or postoperative abdominal scars that could hinder flap vascularization.

Keywords: quilting suture seroma procedure surgery
retrospective evaluation of erector spinae plane blocks

Conditions: Pain, Postoperative

Summary: retrospective evaluation of erector spinae plane blocks

in our institue; we use erector spinae plane block as a part of multimodal analjesia. we want to evaluate block failures and complications related erector spinae plane block. in all patients performed regional anesthesia techniques, we use a regional anesthesia follow chart.

Eligibility criteria:
inclusion criteria: * patient performed erector spinae plane block exclusion criteria: -
ifct-gfpc 05.02 a randomized phase iii trial assessing in patients with advanced non-small cell lung cancer

Conditions: Stage IV Non-small Cell Lung Cancer

Summary: the objective of this trial is to improve the duration of control disease for ps 0-1 patients who are not progressing on first-line cisplatin-gemcitabine chemotherapy. standard therapy is for these patients to stop first-line chemotherapy after 4 to 6 cycles and to begin a second-line chemotherapy when progression of disease is occurring. two approaches will be experimented in this trial in attempt to prolong progression free survival : * maintenance chemotherapy with single-agent gemcitabine continued till disease progression or toxicity. * sequential treatment with erlotinib immediately given after the end of first-line chemotherapy.


Eligibility criteria:
inclusion criteria: * histologically documented nsclc (tumor tissue samples will be provided to look for assessment of egfr status with cish, immunochemistry and mutations) : adenocarcinoma, squamous cell carcinoma, large cell carcinoma. a cytological documentation of nsclc is accepted. * stage iv disease or metastatic relapse in not previously irradiated areas of a nsclc previously treated with surgery or radiation therapy (with a histologically documented proof of relapse) or stage iii b with documented pleural involvement. * measurable disease according to the recist criteria. * prior radiotherapy authorized except for irradiation concerning measurable disease. * age \>18 and \< 70 years. * ps \< 2. * normal hepatic function : serum bilirubin \< 1.5 uln, sgot (asat) and sgpt (alat) \< 2,5 uln ; in presence of liver metastases, sgot and sgpt must be \< 5 x uln. * creatinine clearance \> 60 ml/min. * granulocyte count \> 1,5 giga/l, platelet count \> 100 giga/l. * life expectancy \> 12 weeks. * written (signed) informed consent for use of tumors samples. * written (signed) informed consent to participate in the sudy. exclusion criteria: * small cell lung cancer, bronchiolo-alveolar carcinoma, neuro-endocrine carcinoma. * ps \> 1. * prior chemotherapy other than cisplatin-gemcitabine. * prior therapy with egfr inhibitor (e.g. monoclonal antibody). * no concomitant therapy with phenytoin, carbamazepine, rifampicine or phenobarbital. * concomitant radiotherapy except for localized bone irradiation. * symptomatic brain metastases. * superior vena cava syndrome. * any unstable systemic disease : significant cardiovascular disease including myocardial infarction within the previous year, active infection, significant hepatic or renal disease. * pre-existing interstitial lung disease. * any inflammatory changes of the surface of the eyes. * psychiatric disease with inability to understand the study or to comply with follow-up procedures. * grade \> or = 2 peripheral neuropathy. * any other malignancies within 5 years (except for treated carcinoma in situ of the cervix or basal cell skin cancer). * pregnant or lactating women ; patients with reproductive potential must use effective contraception. * inability to comply with follow-up procedures.

Keywords: non-small cell lung cancer ; metastatic ; chemotherapy ; erlotinib
efficiency of determining the clinical class of chronic venous disorders by artificial intelligence

Conditions: Varicose Veins of Lower Limb; Telangiectasia

Summary: purpose: to evaluate the sensitivity and specificity of the method for determining the clinical class of chronic venous diseases using the ivenus application (within c0-c2 according to ceap). materials and methods: patients who applied to several phlebology clinics for an initial consultation are consistently included in a multicenter prospective study. at the appointment, a doctor with at least 5 years of experience takes photographs of the lower extremities and uploads them to the ivenus application, which automatically determines the clinical class according to ceap, without showing the results to the surgeon (blinding). further, the doctor independently determines the clinical class according to ceap and enters the data into the register. the object of the study is a photograph of a certain area of the lower limb.


Eligibility criteria:
inclusion criteria: * c0-c2 ceap clinical class; * signed consent to take part in investigation. exclusion criteria: * c3-c6 ceap clinical class; * skin diseases of the lower extremities; * immobilization.
safety and efficacy of metformin for treatment of cytopenia in children and adolescents with fanconi anemia

Conditions: Fanconi Anemia

Summary: prospective interventional open-label non-randomized controlled trial to assess safety and efficacy of metformin in treating cytopenia in children and adolescents with fanconi anemia.

fanconi anemia (fa) is a genetic disease characterized by bone marrow failure, cancer susceptibility, and developmental abnormalities. allogeneic hematopoietic stem cell transplantation offers curative therapy for hematologic complications of fa. oxymetholone is commonly used in the management of fa as it improves blood counts, red cells, and platelets. however, its use is limited by its high toxicity profile. metformin is a potential agent that reduces levels of both chromosomal radials and breaks in fa cells and increases the size of the hematopoietic stem cell compartment thus reducing cytopenia in patients with fa.

Eligibility criteria:
inclusion criteria: * age: 5 to 18 years * patients who are diagnosed with fanconi anemia based on clinical features and confirmed by increased chromosomal breakage on diepoxybutane (deb) stress testing. * presence of cytopenia (at least one of the following: hemoglobin (hb) \< 10 g/dl, platelet count \< 100 x 109/l, or an absolute neutrophil count (anc) \< 1.0 x 109/l * patients receiving other therapies e.g., androgens are eligible for enrollment after a one-month washout period before the start of metformin. exclusion criteria: * patients who underwent bone marrow transplantation. * patients with evidence of myelodysplasia, leukemia, or other concurrent malignancy. * patients who have a history of allergic reactions to metformin or similar compounds. * patients with a history of symptomatic hypoglycemia over the past year or hypoglycemia \< 50 mg/dl on screening and baseline laboratory assessments. * patients with type 1 diabetes mellitus. * patients with vitamin b12 deficiency. * patients with glucose-6-phosphate dehydrogenase deficiency. * patients with abnormal kidney function tests including serum creatinine, elevated liver function tests including live enzymes (alt or ast \> 135 u/l, total bilirubin \> 1.5 x upper limit of normal for age, and/or patients with metabolic acidosis (bicarbonate \< 17 meq/l on venous blood gases).
the role of fgf23 and asymmetric dimethylarginine (adma) in chronic kidney disease

Conditions: Metabolic Diseases; Chronic Kidney Disease

Summary: in chronic kidney disease calcium (ca) and phosphate (p) metabolism disorders are very common and also they are one of the leading causes of morbidity in these population. fgf23 is a novel factor that contributes ca-p disorders. it has been hypothesized that fgf 23 increase is mediated by asymmetric dimethylarginine (adma). the aim of the study is to evaluate this hypothesis.


Eligibility criteria:
inclusion criteria: * between ages of 18 - 65 years old * chronic kidney disease of stage 2-4 exclusion criteria: * presence of diabetes mellitus or ischemic hearth disease * taking vitamin d therapy

Keywords: fgf 23 adma chronic kidney disease ca-p metabolism disorder
effect of switching from intermittently scanned to real-time continuous glucose monitoring on diabetes management in adults with type 2 diabetes (switch cgm t2d)

Conditions: Type 2 Diabetes

Summary: the goal of this prospective study is to evaluate diabetes outcomes and patient experience following a switch from second generation intermittently scanned continuous glucose monitor (iscgm) to real-time continuous glucose monitor (rtcgm) compared with participants with continued iscgm use among adults with insulin-treated type 2 diabetes (t2d) in a specialist endocrinology clinic setting in canada. the study aims include: primary outcome - evaluate change in percent time in range (tir) at 3-6 months follow-up after switching from a second generation iscgm system to a rtcgm system compared with participants with continued second generation iscgm use. secondary outcomes - compare glycemic and metabolic outcomes (ie. additional cgm metrics, hba1c, and weight), and outcomes related to diabetes management (ie. self-reported hypoglycemia and change in total daily dose \[tdd\] of insulin) at 3-6 months follow-up in the rtcgm switch and iscgm cohorts among adults with insulin-treated t2d. exploratory outcomes - evaluate patient-reported outcomes (pros) in the rtcgm switch cohort only. pros will include questions about device satisfaction and psychological distress at baseline and 3-6 months follow-up, and protocol-specific questions about dexcom care following use of the rtcgm device at 3-6 months follow-up. additionally this study will compare percent tir, percent tbr, percent tar, and hba1c between rtcgm switch and iscgm cohorts by insulin therapy subgroup (basal vs mdi therapy). rtcgm switch participants will be enrolled at an lmc location and asked to complete pros at baseline and 3-6 month follow-up. continued iscgm participants will not be asked to complete pros.


Eligibility criteria:
inclusion criteria: * 18 years or older * clinical diagnosis of t2d ≥ one year * using insulin for ≥ 6 months * continued freestyle libre® 2 iscgm device (iscgm cohort) as of the study start date * would like to switch from a freestyle libre® 2 iscgm device to a dexcom® g7 rtcgm device (rtcgm switch cohort) as of the study start date * baseline hba1c ≥ 7.5% * known rtcgm/iscgm start date (month and year) * exclusive use of iscgm for ≥ 3 months * data on libreview platforms have percent sensor capture ≥ 70% for 14 days of available data up to 6 months prior to index date * ≥ 1 value for tir (%) up to 6 months (± 6 weeks) prior to index date * ≥ 1 value for hba1c (%) up to 6 months (± 6 weeks) prior to index date * data consent exclusion criteria: * have a prior history of rtcgm within 12 months of the index date * recent or expectant change to antihyperglycemic medications or doses within 30 days of index date * recent or expectant titration of insulin dose ≥ 20% within 30 days of index date * are pregnant at the time of study enrollment or intending to become pregnant during the study * used the iscgm or rtcgm for \< 3 months * using continuous subcutaneous insulin infusion

Keywords: type 2 diabetes continuous glucose monitoring hba1c time in range
study to evaluate the efficacy, safety, and tolerability of an anti-mtbr tau monoclonal antibody (bms-986446) in participants with early alzheimer's disease

Conditions: Alzheimer Disease, Early Onset

Summary: the purpose of this study is to assess the effectiveness, safety, and tolerability of bms-986446 an anti-mtbr tau monoclonal antibody in participants with early alzheimer's disease.


Eligibility criteria:
inclusion criteria * mild cognitive impairment (mci) due to alzheimer's disease (ad) or mild ad dementia consistent with the national institute on aging and the alzheimer's association (nia-aa) core clinical criteria. * global clinical dementia rating (cdr) score of 0.5 to 1.0 and a cdr-memory box score of 0.5 and greater at screening and baseline. * evidence of ad pathology. * objective impairment in episodic memory as indicated by at least 1 standard deviation below age-adjusted mean in the wechsler memory scale iv-logical memory subtest ii (wms-iv lm ii). * mini mental status examination (mmse) score ≥ 20 to 28 (inclusive). exclusion criteria * any evidence of a condition that may affect cognition other than ad. * contraindications to pet imaging. * inability to tolerate or contraindication to magnetic resonance imaging. * any serious medical condition that could, in the opinion of the investigator, affect the participant's safety or interfere with study assessments. * geriatric depression scale (gds) score greater than or equal to 8 at screening. * other protocol-defined inclusion/exclusion criteria apply.

Keywords: alzheimer disease bms-986446 neurodegenerative disease dementia brain diseases anti-mtbr tau monoclonal antibody targettau-1 anti-tau therapy
the effect of the finger feeding method premature babies

Conditions: Premature

Summary: this study aimed to determine the effect of the finger feeding method applied by fathers on the transition time to oral feeding and sucking success in premature babies.

premature babies followed in the neonatal intensive care unit will be randomly divided into two groups: control group and finger-feeding group. babies in the experimental group will be breastfed by their father three times a day. before nasogastric feeding, the baby will be allowed to suck his finger by putting his finger in his mouth for five minutes three times a day. this procedure will be applied three times a day (morning, noon and evening) for a full 7 days. babies in the control group will be given only routine ward care (breast milk or formula via tube without stimulation of the pacifier or mother's finger). preterm baby monitoring form and latch breastfeeding diagnostic measurement tool will be used to determine the transition time to oral feeding and breastfeeding success.

Eligibility criteria:
inclusion criteria: * premature babies at 29-31 weeks * birth weight of 1300 g or more * those whose 1st and 5th minute apgar scores are over 6 * those whose vital signs and health status are stable * in babies who have received mechanical ventilation and continuous positive air pressure support, those who have passed 48 hours after stability has been achieved * no facial or oral anomalies * premature babies without swallowing difficulties * those fed via nasogastric tube * fathers who can read, write and speak turkish * fathers of preterm babies who agreed to participate in the research. exclusion criteria: * those whose vital and health conditions are unstable * those whose father has a skin condition or those who developed it later * any upper respiratory tract infection in the father * premature babies without swallowing difficulties * fathers who cannot read, write or speak turkish * fathers with preterm babies who do not consent to this study will not be included in the scope of the research.

Keywords: premature finger father feeding
effectiveness of high intensity interval training (hiit) on improving cardiometabolic health after sci

Conditions: Metabolic Syndrome; Cardiovascular Diseases

Summary: testing the efficacy of high intensity interval training (hiit), as compared to current research supporting moderate intensity continuous training (mict), as a means to improve cardiometabolic health after spinal cord injury.

this study aims to challenge the effectiveness of the current aerobic exercise recommendations for individuals with spinal cord injuries (sci). currently, moderate intensity continuous training (mict) is suggested however this study intends to explore the effectiveness of high intensity interval training (hiit). to do so, approximately 8 individuals with sci will be undergo a 6 week hiit intervention consisting of 3 sessions per week. with a focus on cardiometabolic health markers (listed in outcome measure section), we aim to provide support for hiit as a viable method of mitigating cardiovascular risk in a sci population.

Eligibility criteria:
inclusion criteria: * individuals with a spinal cord injury (paraplegia or tetraplegia, complete or incomplete) who are at least one-year post injury. * declared medically stable, and able to communicate clearly in english.

Keywords: metabolic syndrome spinal cord injury cardiovascular disease high intensity interval training
the role of microparticles as a biomarker

Conditions: Atypical Hemolytic Uremic Syndrome; Thrombotic Thrombocytopenic Purpura; Microparticles; Microangiopathic Hemolytic Anemia

Summary: the investigators propose to characterize mps in ahus and ttp both at the onset and throughout treatment. the investigators believe that the number, size, and cell origin of mps will differ between these two diseases. the hypothesis is that endothelial derived mps will be higher in number and comprise a larger portion of the mp population in ahus and that platelet mps will comprise a larger number and greater proportion of mps in ttp. the investigators believe that mp identity and number can be used to reliably differentiate between ahus and ttp at disease onset.


Eligibility criteria:
inclusion criteria: * patients with maha, ttp, and/or ahus exclusion criteria: * prisoners
a novel approach to reducing adiposity among young men

Conditions: Weight Loss; Men; Lifestyle Risk Reduction; Cardiovascular Diseases; Obesity

Summary: the purpose of this research study is to find out whether a primarily self-guided program can produce changes in weight, body fat and cardiovascular risk among young men.

this self-guided lifestyle intervention may help men to reduce weight and improve heart health because it has been adapted to meet the possible weight loss needs of young men. young men may experience reductions in body weight after enrollment in the intervention, but this is unknown. study participation lasts approximately 3 months. participants will be assessed by the study staff and fill out questionnaires about current lifestyle practices (diet, physical activity, sleep habits, risk behaviors). weight, medical events, and medication use within the last 3 months will be assessed. eligible participants will be randomly assigned (like the flip of a coin) to the control group or self-guided group.

Eligibility criteria:
inclusion criteria: 1. self-identify as a man 2. 18-35 years old 3. bmi 25-45kg/m2 4. live in north america exclusion criteria: 1. an uncontrolled medical condition that might make it unsafe to change their eating or engage in unsupervised physical activity (e.g., uncontrolled hypertension) 2. a diagnosis of type 1 or type 2 diabetes 3. report a heart condition, chest pain during periods of activity or rest, or loss of consciousness on the physical activity readiness questionnaire (par-q), which will be administered during prescreen 4. currently enrolled in another weight loss program, taking weight loss medication or history of weight loss surgery 5. change in medication(s) within the last 3 months that could influence weight (e.g., steroids) 6. have lost \> 5% body weight within the last 3 months 7. report a history of anorexia nervosa or bulimia nervosa or any compensatory behaviors within the previous 3 months 8. report hospitalization for a psychiatric condition within the last year 9. report high alcohol intake (audit score \> 16). 10. are not able to speak and read english 11. do not possess a mobile device or are unwilling to use it to receive study text messages 12. given strict data regulations outside of north america (i.e., europe), we will only include participants living in north america (i.e., united states, canada).